Christian Ruff, MD

Christian Ruff, MD

Christian Ruff, MD

Principal Investigator, ENGAGE-AF Trial

TIMI Group

Director, General Cardiology

Brigham and Women’s Hospital

Assistant Professor of Medicine

Harvard Medical School

Boston, MA

Related Videos

You have noted that 70 mg/dL is the “AHA Guideline” threshold for the LDL-C level in high-risk patients, but when in your view is more aggressive lowering to levels such as those observed in the ODYSSEY Outcomes and FOURIER trials justified? Video

You have noted that 70 mg/dL is the “AHA Guideline” threshold for the LDL-C level in high-risk patients, but when in your view is more aggressive lowering to levels such as those observed in the ODYSSEY Outcomes and FOURIER trials justified?

How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines? Video

How have the trifecta of recent developments—associated, all-cause mortality reduction reported in ODYSSEY Outcomes, price reduction of PCSK9 inhibitors, and new AHA Guidelines—affected your approach to deploying these agents at the front lines?

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this? Video

ODYSSEY Outcomes reports that post-ACS patients with starting LDL-C levels greater than 100 mg/dL benefited most, but you have noted the importance of assessing “aggregate risk” when identifying triggers for PCSK9-based therapy. Can you discuss this?

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines? Video

In your framing of “aggregate ASCVD risk” as a stimulant to extremely aggressive LDL-C lowering, what clinical signature should compel the general cardiologist to translate the results with alirocumab in ODYSSEY Outcomes to the front lines?